GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Operating Income

Medincell (XPAR:MEDCL) Operating Income : €-20.98 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Medincell Operating Income?

Medincell's Operating Income for the six months ended in Mar. 2024 was €-11.99 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was €-20.98 Mil.

Warning Sign:

Medincell SA has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Medincell's Operating Income for the six months ended in Mar. 2024 was €-11.99 Mil. Medincell's Revenue for the six months ended in Mar. 2024 was €2.18 Mil. Therefore, Medincell's Operating Margin % for the quarter that ended in Mar. 2024 was -551.40%.

Good Sign:

Medincell SA operating margin is expanding. Margin expansion is usually a good sign.

Medincell's 5-Year average Growth Rate for Operating Margin % was 24.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medincell's annualized ROC % for the quarter that ended in Mar. 2024 was -91.26%. Medincell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -418.34%.


Medincell Operating Income Historical Data

The historical data trend for Medincell's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Operating Income Chart

Medincell Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Operating Income
Get a 7-Day Free Trial Premium Member Only -19.33 -15.58 -23.82 -24.05 -20.98

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.60 -11.66 -12.39 -8.98 -11.99

Medincell Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-20.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medincell  (XPAR:MEDCL) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medincell's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-23.986 * ( 1 - -0.52% )/( (28.764 + 24.074)/ 2 )
=-24.1107272/26.419
=-91.26 %

where

Note: The Operating Income data used here is two times the semi-annual (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medincell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-29.148/( ( (5.762 + max(2.739, 0)) + (5.434 + max(-2.526, 0)) )/ 2 )
=-29.148/( ( 8.501 + 5.434 )/ 2 )
=-29.148/6.9675
=-418.34 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.053 + 0 + 10.452) - (2.149 + 0 + 7.617)
=2.739

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.254 + 0 + 5.525) - (2.082 + 0 + 8.223)
=-2.526

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Medincell's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-11.993/2.175
=-551.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Medincell Operating Income Related Terms

Thank you for viewing the detailed overview of Medincell's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Medincell Business Description

Traded in Other Exchanges
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell Headlines

No Headlines